Radiation‐Induced Immunogenic Cell Death for Cancer Radioimmunotherapy
Small Methods · 2023-05 · 7 (5)
DOI: 10.1002/smtd.202201401 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Small Methods, online erschienen am 21.02.2023. Verfasst von Teng Liu und 4 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Radiation Medicine and Protection, School of Radiation Medicine and Protection & School for Radiological and Interdisciplinar…. Hauptthemen laut MEDLINE: Radioimmunotherapy, Neoplasms. Die Arbeit wurde bisher 98-mal zitiert (Crossref) und nennt 132 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Key Research and Development Program of Social Development of Jiangsu Province, Natural Science Foundation of Jiangsu Province.
Abstract (Originalsprache)
In cancer treatment, traditional radiotherapy (RT) is routinely conducted in local tumors and limited by radioresistance, while recently emerged immunotherapy is confronted with low response rate, high cost, and cytokine release syndrome. Logically, the combination of the two therapeutic modalities into radioimmunotherapy is promising to complement with each other for systemic elimination of cancer cells with high specificity, efficiency, and safety. Especially, RT‐induced immunogenic cell death (ICD) plays an imperative role in radioimmunotherapy to evoke systemic immune response against cancer, including elevating the immunity of tumor antigens, recruiting and activating antigen‐presenting cells, and priming cytotoxic T lymphocytes for tumoral infiltration and cancer cell eradication. This review first retrospects the origin and concept of ICD, summarizes the major damage‐associated molecular patterns and signaling pathways, and highlights the characteristics of RT‐induced ICD. Subsequently, therapeutic strategies enhancing RT‐induced ICD for radioimmunotherapy are reviewed from the perspectives of enhancing RT itself, combination with other treatments, and stimulating the holistic immune system. On the basis of these published research and underlying mechanism, this work attempts to forecast possible directions for RT‐induced ICD enhancement to promote clinical applications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- State Key Laboratory of Radiation Medicine and Protection, School of Radiation Medicine and Protection & School for Radiological and Interdisciplinary Sciences (RAD-X), Collaborative Innovation Center of Radiation Medic…
ORCID-Profile: Kai Yang
Förderung
- National Natural Science Foundation of China
- Key Research and Development Program of Social Development of Jiangsu Province
- Natural Science Foundation of Jiangsu Province
- Priority Academic Program Development of Jiangsu Higher Education Institutions
Zitieren
APA
Liu, T., Pei, P., Shen, W., Hu, L., & Yang, K. (2023). Radiation‐Induced Immunogenic Cell Death for Cancer Radioimmunotherapy. Small Methods, 7(5). https://doi.org/10.1002/smtd.202201401
Vancouver
Liu T, Pei P, Shen W, Hu L, Yang K. Radiation‐Induced Immunogenic Cell Death for Cancer Radioimmunotherapy. Small Methods. 2023;7(5). doi:10.1002/smtd.202201401
BibTeX
@article{Liu2023,
author = {Liu, Teng and Pei, Pei and Shen, Wenhao and Hu, Lin and Yang, Kai},
title = {Radiation‐Induced Immunogenic Cell Death for Cancer Radioimmunotherapy},
journal = {Small Methods},
year = {2023},
volume = {7},
number = {5},
doi = {10.1002/smtd.202201401}
}
EUVIMED